Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Tuberculosis

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The tuberculostatic activity of intermediate compounds of chloramphenicol.

Antibiotics & chemotherapy (Northfield, Ill.)·2014

Same author

Sexually transmitted diseases in Canada: an overview.

Canadian family physician Medecin de famille canadien·2011

Same author

Simplified isoniazid acetylator phenotyping.

Canadian Medical Association journal·2010

Same author

Invitation to contribute to aspects of national immunization policy.

Canadian Medical Association journal·2010

Same author

Thymidylate synthase expression in stage II and III colon cancer: a retrospective review.

American journal of clinical oncology·2002

Same author

Human T-lymphotropic virus 1 adult T-cell lymphoma with Giardia and Strongyloides parasitism.

Archives of pathology & laboratory medicine·2000

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Drug therapy of tuberculosis.

A G Jessamine, L Eidus

Canadian Family Physician Medecin De Famille Canadien

|May 15, 2010

Summary

For new tuberculosis patients, standard treatment uses Isoniazid, PAS, and Streptomycin. Newer drugs like Rifampin and Ethambutol are reserved for specific cases pending further trial results.

Area of Science:

Pulmonology
Infectious Diseases
Pharmacology

Background:

Tuberculosis (TB) treatment relies on established first-line drugs.
Emerging drug resistance and hypersensitivity necessitate exploring alternative therapies.
Newer antitubercular agents offer potential but require rigorous evaluation.

Purpose of the Study:

To outline current recommendations for first-line tuberculosis treatment.
To define the appropriate use of newer antitubercular drugs in specific patient populations.
To emphasize the need for ongoing therapeutic trials for novel drug integration.

Main Methods:

Review of established tuberculosis treatment guidelines.
Analysis of indications for using recently introduced antitubercular drugs.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Related Experiment Videos

Last Updated: Jun 13, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Consideration of ongoing clinical trials for drug efficacy and safety.

Main Results:

Preference for Isoniazid, PAS, and Streptomycin in previously untreated TB patients.
Newer drugs (Rifampin, Ethambutol) are recommended for specific scenarios.
Deferral of PAS substitution until further therapeutic trial data is available.

Conclusions:

Standard first-line therapy remains the initial approach for new TB cases.
Newer agents are crucial for salvage therapy and drug-resistant TB.
Further research is essential to guide the optimal integration of novel antitubercular drugs.